Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1
Our novel screening platform can therefore be used in the future to identify novel immunomodulators and pathways in cancer and inflammation, expanding therapeutic horizons.
Authors
- Ophir Hay
- Lika Gamaev
- Devorah Olam
- Hanna Wald
- Ori Wald (ORCID: https://orcid.org/0000-0002-8189-0716)
- Michal Abraham (ORCID: https://orcid.org/0000-0002-7122-8630)
- Shira Hagbi-Levi (ORCID: https://orcid.org/0000-0002-2891-0079)
- Amnon Peled
- Lola Weiss
- Inbal Mishaelian
- Elina Zorde-Khevalevsky
Institutions
- Israel Institute for Biological Research (IL)
- Hadassah Medical Center (IL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1502094
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Teva Pharmaceutical Industries
- Hebrew University of Jerusalem